| Wang, Jie |
NCT03476083: Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission |
|
|
| Recruiting | 4 | 280 | RoW | Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily., HBIg 200 IU im for infants in the group B, HBV vaccine 10 ug im for all infants | New Discovery LLC | Hepatitis B Infection, Congenital Malformation, Birth Defect, Viremia, Chronic Infection | 05/21 | 05/24 | | |
NCT04381143: ASPIrin in Reducing Events in Dialysis ( ASPIRED ) |
|
|
| Recruiting | 4 | 9000 | RoW | Aspirin 100 mg Oral Tablet, Matching Placebo | Guangdong Provincial People's Hospital, The George Institute | CKD (Chronic Kidney Disease) Stage 5D | 09/26 | 12/26 | | |
NCT05860907: Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis |
|
|
| Not yet recruiting | 4 | 384 | RoW | Huaier Granule, Z20000109（NMPA Approval Number） | Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Breast Cancer Stage IV | 10/25 | 10/27 | | |
| Completed | 3 | 360 | RoW | Tislelizumab, BGB-A317, Tevimbra, Paclitaxel, Nab-paclitaxel, Carboplatin | BeiGene | Non-Small Cell Lung Cancer | 09/20 | 04/23 | | |
|
|
|
|
ACROSS2, NCT04500717: Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation |
|
|
| Not yet recruiting | 3 | 460 | RoW | Almonertinib, Aleime, Almonertinib plus carboplatin and pemetrexed | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Non Small Cell Lung Cancer | 10/22 | 10/23 | | |
BL-B01D1-302, NCT06382129: A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 604 | RoW | BL-B01D1, Docetaxel | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 05/26 | 05/26 | | |
SACHI, NCT05015608: Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification |
|
|
| Recruiting | 3 | 250 | RoW | Savolitinib + Osimertinib, Pemetrexed + Cisplatin /Carboplatin | Hutchison Medipharma Limited | Non-small Cell Lung Cancer | 09/24 | 11/24 | | |
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations |
|
|
| Not yet recruiting | 3 | 350 | RoW | YK-209A tablet, Pemetrexed+carboplatin/Cisplatin | Suzhou Puhe Pharmaceutical Technology Co., LTD | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 07/25 | 12/26 | | |
AK104-307, NCT05990127: A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 642 | RoW | AK104, Tislelizumab, carboplatin, Pemetrexed, Paclitaxel | Akeso | Locally Advanced or Metastatic NSCLC | 08/25 | 11/26 | | |
NCT03418779: Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD |
|
|
| Active, not recruiting | 2/3 | 60 | RoW | The Yi-Qi-Qing-Jie herbal compound, Immunosuppressants, prednisolone, cyclophosphamide, Optimized Supportive Care, Yi-Qi-Qing-Jie herbal compound placebo | Guang'anmen Hospital of China Academy of Chinese Medical Sciences, China Academy of Chinese Medical Sciences | IgA Nephropathy at High Risk of Developing ESRD | 09/24 | 12/24 | | |
JACKPOT33, NCT06198907: Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) |
|
|
| Not yet recruiting | 2 | 69 | RoW | Golidocitinib, Sintilimab, platinum doublet chemotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Dizal Pharmaceuticals | Non-Small-Cell Lung Cancer | 12/26 | 12/27 | | |
NCT06452433: Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer. |
|
|
| Not yet recruiting | 2 | 91 | NA | gumarontinib, SCC244, third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib), third-generation EGFR-TKI | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Non-small Cell Lung Cancer | 12/27 | 02/28 | | |
NCT04747236: Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL |
|
|
| Recruiting | 2 | 50 | US | Azacytidine, Vidaza, Romidepsin, Istodax, Belinostat, Beleodaq, Pralatrexate, Folotyn, Gemcitabine, Gemzar | University of Virginia, Celgene | PTCL | 06/26 | 06/28 | | |
NCT04858256: Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms |
|
|
| Recruiting | 2 | 100 | US | Pacritinib | University of Michigan Rogel Cancer Center, National Institutes of Health (NIH), National Cancer Institute (NCI) | T-Cell Neoplasm, Lymphoproliferative Disorders | 11/27 | 11/28 | | |
NCT05000684: Study of JS004 Combined With Toripalimab for Advanced Lung Cancer |
|
|
| Recruiting | 1/2 | 66 | RoW | JS004 in combination with toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Advanced Lung Cancer | 08/23 | 08/24 | | |
NCT05767866: Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR |
|
|
| Recruiting | 1/2 | 160 | RoW | YK-029A | Suzhou Puhe Pharmaceutical Technology Co., LTD | Treatment, Treatment Side Effects | 12/23 | 05/24 | | |
NCT04930432: Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors |
|
|
| Recruiting | 1/2 | 400 | RoW | MCLA-129 | Betta Pharmaceuticals Co., Ltd. | Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer | 04/28 | 12/28 | | |
NCT05944185: Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 42 | RoW | αPD1-MSLN-CAR T Cells | Shanghai Cell Therapy Group Co.,Ltd, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Advanced Solid Tumor | 09/24 | 09/25 | | |
NCT05645276: A Study of AK129 in Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1a/1b | 182 | RoW | AK129 IV infusion | Akeso | Advanced Malignant Tumors(Stage IA-IB) | 02/25 | 02/25 | | |
| Recruiting | 1 | 114 | RoW | TSN084 | Tyligand Bioscience (Shanghai) Limited | Malignant Neoplasm | 12/25 | 06/26 | | |
NCT04672928: A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies |
|
|
| Completed | 1 | 20 | RoW | paclitaxel, IBI318 | Innovent Biologics (Suzhou) Co. Ltd. | Small Cell Lung Carcinoma | 01/23 | 01/23 | | |
NCT05895812: A Study in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function |
|
|
| Completed | 1 | 24 | RoW | Deuremidevir Hydrobromide Tablets | Shanghai Vinnerna Biosciences Co., Ltd., Sponsor GmbH | Subjects With Renal Impairment, Healthy Subjects | 08/23 | 08/23 | | |
NCT05514132: A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours |
|
|
| Active, not recruiting | 1 | 14 | RoW | Ceralasertib, Ceralasertib taken orally, Durvalumab, Durvalumab Infusion | AstraZeneca | Advanced Solid Tumours | 10/23 | 04/25 | | |
| Recruiting | 1 | 177 | RoW | HS-20093 (Phase Ia: Dose escalation), HS-20093 (Phase Ib: Dose expansion) | Shanghai Hansoh Biomedical Co., Ltd | Advanced Solid Tumor | 12/23 | 12/23 | | |
NCT05089266: Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | CAR T cells | Shanghai Cell Therapy Group Co.,Ltd | Colorectal Cancer | 07/24 | 01/25 | | |
NCT06115642: A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 36 | RoW | HLX43, Anti-PD-L1 ADC | Shanghai Henlius Biotech | Advanced Solid Tumor | 06/25 | 11/25 | | |
NCT05886439: LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer |
|
|
| Recruiting | 1 | 40 | RoW | LK101 injection (personlized neoantigen pulsed DC vaccine ), Pembrolizumab, Durvalumab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Advanced Lung Carcinoma | 07/25 | 12/26 | | |
NCT06054932: Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors |
|
|
| Recruiting | 1 | 18 | RoW | LK101 injection | Beijing Likang Life Science and Tech Co., Ltd. | Advanced Solid Tumor | 12/25 | 03/26 | | |
NCT01133951: Helicobacter Pylori Eradication to Prevent Gastric Cancer |
|
|
| Active, not recruiting | N/A | 3000 | RoW | OAC triple therapy, Placebo | Jie-Jun Wang | Helicobacter Infections, Stomach Neoplasms | 01/12 | 05/32 | | |
| Not yet recruiting | N/A | 14026 | RoW | | Guangzhou Burning Rock Dx Co., Ltd. | Cancer | 10/22 | 03/23 | | |
| Recruiting | N/A | 14026 | RoW | Multi-cancer early detection test | Shanghai Zhongshan Hospital, Guangzhou Burning Rock Dx Co., Ltd. | Cancer | 12/22 | 03/23 | | |
| Recruiting | N/A | 11879 | RoW | Multi-cancer early detection test | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Guangzhou Burning Rock Dx Co., Ltd. | Cancer | 03/23 | 06/23 | | |
NCT06704074: Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients |
|
|
| Not yet recruiting | N/A | 120 | RoW | virtual reality (VR) head mounted display | Qilu Hospital of Shandong University, First Affiliated Hospital of Chongqing Medical University, Shanghai Yangzhi Rehabilitation Hospital, Beihang University, Huashan Hospital | Stroke | 05/26 | 11/26 | | |
| Recruiting | N/A | 87 | RoW | Favourate taste stimulation, Sour taste stimulation, Thermal stimulation group | Qilu Hospital of Shandong University, Shandong University | Stroke, Dysphagia | 01/25 | 07/25 | | |
| Recruiting | N/A | 1332 | RoW | The lying flat (0°-10°) head position for 72 hours, The The head elevation (30°-40°) position for 72 hours | Zhengzhou Yuan | Stroke, Acute, Endovascular Therapy | 11/25 | 04/26 | | |
| Completed | N/A | 2305 | RoW | Multi-cancer early detection test | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Guangzhou Burning Rock Dx Co., Ltd. | Cancer | 03/22 | 06/22 | | |
| Wang, Xi |
NCT02461043: Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 386 | RoW | paclitaxel; cisplatin, radiation | Chinese Academy of Medical Sciences | Esophageal Cancer | 12/20 | 12/23 | | |
NCT01133951: Helicobacter Pylori Eradication to Prevent Gastric Cancer |
|
|
| Active, not recruiting | N/A | 3000 | RoW | OAC triple therapy, Placebo | Jie-Jun Wang | Helicobacter Infections, Stomach Neoplasms | 01/12 | 05/32 | | |
